Viridian Therapeutics Inc

NASDAQ:VRDN   3:59:53 PM EDT
16.68
+0.13 (+0.78%)
Products, Regulatory

Viridian Therapeutics Inc Submits Investigational New Drug Application For VRDN-001 To The U.S. Food And Drug Administration

Published: 10/14/2021 12:13 GMT
Viridian Therapeutics Inc (VRDN) - Viridian Therapeutics Submits Investigational New Drug Application for Vrdn-001, an Igf-1r Antibody for the Treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration.
Viridian Therapeutics Submits Investigational New Drug Application for Vrdn-001, an Igf-1r Antibody for the Treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration.
Viridian Therapeutics Inc - Vrdn-001 Program Remains on Track for Key Proof of Concept Clinical Data in Thyroid Eye Disease Patients in Q2 of 2022.